New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:37 EDTCGIXCancer Genetics adds additional kidney cancer patent to portfolio
Cancer Genetics announced that the U.S. Patent and Trademark Office has allowed its patent claims related to the company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample. The patent application is expected to obtain an issued patent number during 2Q14. This latest patent builds on the intellectual property portfolio the company has already gained for kidney cancer diagnostics. New data further validating CGI's UroGenRA Kidney test will be presented on March 3 at the annual U.S. & Canadian Academy of Pathology meeting. In the study, 191 pathology specimens from renal cancer patients were analyzed using CGI's proprietary genomic microarray test, which enables accurate classification of kidney cancer among the four major subtypes and predicts whether the cancer is benign or malignant. The test has been validated to work across sample types ranging from fine-needle aspirate to paraffin-embedded and formalin-fixed tissue, making it widely usable for both new cases as well as cases that are not diagnosable using traditional methods
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:45 EDTCGIXCancer Genetics awarded multimillion dollar clinical trial
Cancer Genetics announced that it has been awarded a multimillion dollar, clinical trial in hematological cancers by a leading biotech company the trial is the largest in the company's history of providing clinical trial and genomic services to global biopharma companies. As part of the agreement, CGI will perform all testing, and provide genomic information and monitoring for CLL patients enrolled in multi-arm, randomized, multicenter, global trials. The CLL trials are expected to contribute up to $6.2M in revenue over several years as patients are selected, treated, and monitored using pathway-specific, targeted therapies, and combination therapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use